Syngeneic Tumor Models

Evaluate your immunotherapies and fast-track their in vivo screening


Large Panel of Validated Syngeneic Models Ready for Your Immunotherapy Evaluation

Preclinical research into new immunotherapies requires in vivo models with fully functional immunity. Syngeneic tumor models are allografts derived from immortalized mouse cancer cell lines which originated from the same inbred strain of mice. This provides simple models with fully competent immunity for assessing your new single agent and combination immunotherapies.

We provide a large collection of over 40 syngeneic models covering a variety of cancer types, available now for your efficacy studies.

Subcutaneous Models

Bladder: MBT-2
Colon: Colon-26, CT26.WT, MC38
Glioma: GL261 Red-Fluc
Leukemia: C1498
Lung: KLN205, LL/2(LLC1)
Melanoma: B16-BL6, B16-F0,
B16-F1, B16-F10
Neuroblastoma: N1E-115, Neuro-2a
Prostate: RM-1
Breast: 4T-1, EMT6, JC
Fibrosarcoma: WEHI 164
Kidney: Renca
Liver: H22, Hepa 1-6
Lymphoma: A20, E.G7-OVA, EL4, L5178-R(LY-R)
Myeloma: MPC-11, J558, P3X63Ag8U.1
Pancreatic: Pan02

Orthotopic Models

Breast: 4T-1, EMT6
Liver: Hepa 1-6
Glioma: GL261 Red-Fluc
Pancreatic: Pan02

Systemic Models

Leukemia: C1498
Myeloma: MPC-11
Lymphoma: A20, E.G7-OVA, EL4, L5178-R(LY-R)
Lung: LL/2(LLC1)

Specialty Models

Breast: 4T-1 (metastatic/bioluminescent, orthotopic)
Liver: H22 (orthotopic/bioluminescent) Hepa 1-6 (orthotopic/bioluminescent)

Well Validated Models

Our syngeneic models are well characterized, making them the ideal models to evaluate your novel immuno-oncology agents as well as combination therapies.

Evaluation of Anti-PD-1 Efficacy

The extensive characterization data found within our searchable database MuBase® includes immune checkpoint inhibitor benchmarking (including model response to anti-PD-1, PD-L1, and CTLA-4) and tumor RNAseq. Baseline tumor immunoprofiling is also available for a subset of our models with further characterization ongoing.

Advanced Models for Metastatic Modeling and Optical Imaging 

Discover Large Scale In Vivo Screening for Immunotherapeutics